Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03716518
Other study ID # 2017YFC1700604
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date December 12, 2018
Est. completion date May 31, 2021

Study information

Verified date November 2020
Source Xiyuan Hospital of China Academy of Chinese Medical Sciences
Contact Yufei Yang, M.D.
Phone 8613701366913
Email yyfwdbwyy@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to:(1) determine the efficacy of Traditional Chinese Medicine (TCM) 'Tonifying Spleen and Kidney Sequential Regimen' (TSKSR) in improving the completion rate of 8-cycle CapeOX chemotherapy in patients with stage II (high-risk)& III colon cancer;(2) evaluate the efficacy of the TCM-TSKSR on adverse events of CapeOX chemotherapy and it's impact on patients' quality of life (QoL).A randomized,double-blinded,placebo-controlled clinical trial including seven centers will be conducted in Mainland China.The study will enroll patients with stage II (high-risk)& III colon cancer who have completed radical surgery and are going to receive CapeOX chemotherapy.All participants will receive chemotherapy as prescribed by their treating physicians and be randomly assigned to either concurrent use of TCM-TSKSR or placebo.


Description:

CapeOX chemotherapy is a combination therapy of Oxaliplatin 130mg/m^2 IV on 1st day and Capecitabine 1000mg/m^2 PO twice daily from 1th day to 14th day,21 days for each course of treatment.Adverse effects of chemotherapy,such as myelosuppression and gastrointestinal reactions,may lead to dose reductions,treatment delays or even discontinuation among cancer patients. According to IDEA study,the completion rate of 8-cycle CapeOX chemotherapy in colorectal cancer patients is 64%,which means that nearly 4 in 10 patients could not complete adjuvant chemotherapy as planned,which may negatively impact patients' survival outcomes.Some prior studies have shown that TCM can improve patients' symptom control and QoL during adjuvant chemotherapy,which may further improve the completion of adjuvant chemotherapy. However,there is a lack of definitive evidence to evaluate the effects of TCM in stage II(high-risk)& III colon cancer patients who receive adjuvant chemotherapy after radical surgery.The study will be conducted between 2018 and 2021.Four hundred participants will be enrolled and randomly assigned to either the experimental group or the control group.


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date May 31, 2021
Est. primary completion date May 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patient with pathological diagnosis of colon cancer; no residual tumor at the resection margin. - tumor-node-metastasis(TNM)Stage II (high-risk)or III colon cancer according to 8th edition of American Joint Committee on Cancer(AJCC)Staging Manual. High-risk stage II disease is characterized by at least one of the following: 1. T4 tumor, 2. inadequately sampled nodes (<12 lymph nodes), 3. clinical presentation with bowel obstruction or perforation, 4. poorly differentiated histology ,exclusive of those cancers that are High degree of microsatellite instability(MSI-H), 5. lymphovascular invasion,perineural invasion(PNI). - Underwent radical surgery no more than six weeks ago and plan to start chemotherapy. - Have not been enrolled in other therapeutic clinical trials within the near 30 days. - Age between 18 to 75 years; All genders; Eastern Cooperative Oncology Group - performance status(ECOG-PS)from 0 to 2; Women who are pregnant, lactating or of reproductive age are not eligible, while those of reproductive age using secure contraceptives are eligible. - No history of previous malignancy other than adequately treated in situ carcinoma of the uterine cervix or basal or squamous cell carcinoma of the skin, unless there has been a disease-free interval of at least 5 years. - Laboratory testing: blood routine examination: WBC=3.5×109/L,NEUT=1.5×109/L,PLT=100×109/L,HGB=90g/L;biochemical tests:TBIL=1.5×ULN,AST(SGOT),ALT(SGPT)=2.5×ULN,Scr=1.5×ULN;CEA after surgery was normal. - Consented. - Agree not to be enrolled in other interventional studies during the research. Exclusion Criteria: - Patients not suitable for chemotherapy of CapeOX ,which will be determined by the investigator or the attending physician. - Clinically relevant cardiovascular and/or cerebrovascular disease,active hepatitis,severe abnormalities in liver/ renal function tests. - Known allergy to any of the components of study drug. - Those who cannot take the study drug orally because of bowel obstruction and/or require for peripheral vein nutrition. - Malabsorption or diseases that affect the absorption. - Unstable situations or situations that may endanger the safety of patients and their compliance, such as severe mental illness,schizophrenia. - Colostomy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tonifying Spleen and Kidney Sequential Regimen
TSKSR will be given to the participants as follows:Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and Qi-tu-er-zhi Granule,1 pack each time,twice a day,PO,from 7th to 20th day of chemotherapy.
Placebo of 'Tonifying Spleen and Kidney Sequential Regimen
Placebo of TCM-TSKSR will be given to the participants as follows:placebo of Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and placebo of Qi-tu-er-zhi Granule,1 pack each time,twice a day,from 7th to 20th day of chemotherapy.

Locations

Country Name City State
China Beijing Cancer Hospital Beijing Beijing
China Beijing Chao Yang Hospital Beijing Beijing
China Civil Aviation General Hospital Beijing Beijing
China Oncology Department of Xiyuan Hospital of China Academy of Chinese Medical Sciences Beijing Beijing
China Chongqing University Cancer Hospital Chongqing Chongqing
China Guangdong Provincial Hospital of Traditional Chinese Medicine Guangdong Guangzhou
China Jiangsu Province Hospital of Traditional Chinese Medicine Nanjing Jiangsu
China Shanghai Zhongshan Hospital Shanghai Shanghai
China Tianjin Union Medical Center Tianjin Tianjin
China Henan Provincial People's Hospital Zhengzhou Henan
China The Third People's Hospital of Zhengzhou Zhengzhou Henan
China Zhengzhou Hospital of Traditional Chinese Medicine Zhengzhou Henan

Sponsors (13)

Lead Sponsor Collaborator
Xiyuan Hospital of China Academy of Chinese Medical Sciences Beijing Cancer Hospital, Beijing Chao Yang Hospital, Beijing University of Chinese Medicine, Chongqing University Cancer Hospital, Civil Aviation General Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Henan Provincial People's Hospital, Jiangsu Province Hospital of Traditional Chinese Medicine, Peking University Third Hospital, Shanghai Zhongshan Hospital, Tianjin Union Medical Center, Zhengzhou Hospital of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Completion Rate of 8-cycle Adjuvant Chemotherapy Completion Rate of 8-cycle Adjuvant Chemotherapy=number of participants completing 8-cycle adjuvant chemotherapy/number of participants randomized to each group*100% 6months
Secondary Completion Rate of Adjuvant Chemotherapy of Each Participant Completion Rate of Adjuvant Chemotherapy of Each Participant=number of the last courses of chemotherapy/8*100% 6months
Secondary Completion Rate of 4-cycle Adjuvant Chemotherapy Completion Rate of 4-cycle Adjuvant Chemotherapy=number of participants completing 4-cycle adjuvant chemotherapy/number of participants randomized to each group*100% 3months
Secondary Time to Treatment Failure,TTF TTF is the period from randomization to the earliest day of an event such as withdrawal from protocol treatment for any reasons, patients refusal and loss to follow-up. 6months
Secondary Relative Dose Intensity (RDI) of Adjuvant Chemotherapy Relative dose intensity (RDI) (%) = (actual dose/ initial dose of adjuvant chemotherapy) × 100% 6months
Secondary Proportion of Modifications of Time Proportion of Modifications of Time=number of participants delaying chemotherapy /number of participants randomized to each group*100%.Delay is defined as =7days because of adverse event,such as weakness, myelosuppression, gastrointestinal reactions and other toxicity,except for administrative issues related to hospitalization. 6months
Secondary Time of Dose Reductions of Adjuvant Chemotherapy for the First Time It is the period from randomization to when a chemo-induced grade 3-4 granulocytopenia and/or a chemo-induced grade 2 thrombocytopenia is observed in participants for the first time,in which case,the dose of both Oxaliplatin and Capecitabine will be reduced by 25% of planned dosage. 6months
Secondary Time of Dose Reductions of Adjuvant Chemotherapy for the Second Time It is the period from randomization to when a chemo-induced grade 3-4 granulocytopenia and/or a chemo-induced grade 2 thrombocytopenia is observed in participants for the second time,in which case,the dose of both Oxaliplatin and Capecitabine will be reduced by 50% of planned dosage. 6months
Secondary Proportion of Salvage Treatment Proportion of Salvage Treatment=Number of participants receiving salvage treatment/Number of participants randomized to each group*100%. 6months
Secondary Incidence of a Chemo-induced Grade 3-4 Nausea/Vomiting 6 months
Secondary Incidence of a Chemo-induced Grade 2 Diarrhea 6 months
Secondary Changes of Participants' ESAS Score Edmonton Symptom Assessment Scale(ESAS) score will be used to evaluate the change of participants' QoL during adjuvant chemotherapy.ESAS has 9 items designed to assess the severity of commonly reported symptoms experienced by cancer patients,including pain, fatigue, drowsiness, nausea, dyspnea, depression, anxiety, well-being, and loss of appetite.Each items ranges from 0 to 10. 6 months
Secondary Changes of Participants' FACT-C Score Functional Assessment of Cancer Therapy-Colorectal (FACT-C) score will be used to evaluate the change of participants' QoL during adjuvant chemotherapy.The FACT-C consists of 36 items,in four domains of well-being (physical,emotional,social,and functional),on a scale of 0 to 4. 6months
Secondary Changes of TCM Symptoms Score Based on a prior expert consensus,11 TCM symptoms were considered to be the most common symptoms during CapeOX chemotherapy,including vomiting, numbness, diarrhea, constipation, sensation of chill, nocturia, forgetfulness, spontaneous sweating, night sweats, dry mouth and canker sores, each of which ranges from 0 to 10. 6months
Secondary Changes of Spleen Deficiency Scale Score Based on prior researches,the investigator designed Spleen Deficiency Scale,which includes 8 items involving appetite,abdominal distension and so on.Each question ranges from 1 to 5. 6months
Secondary Changes of Kidney Deficiency Scale Score Based on prior researches,the investigator designed Kidney Deficiency Scale, which includes 8 items involving soreness of waist, tinnitus, and so on. Each question ranged from 1 to 5. 6months
Secondary Incidence of AEs Adverse effects(AEs) includes abnormal results of blood/urine/stool routine examination, liver/renal function test and electrocardiograms. 6months
Secondary Incidence of SAEs Serious Adverse effects(SAEs) includes abnormal results of blood/urine/stool routine examination, liver/renal function test and electrocardiograms. 6months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT03457454 - Reducing Rural Colon Cancer Disparities
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Completed NCT03390907 - Hybrid APC Assisted EMR for Large Colon Polyps N/A
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT04079478 - The AID Study: Artificial Intelligence for Colorectal Adenoma Detection
Active, not recruiting NCT04057274 - Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth N/A
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Not yet recruiting NCT05147545 - Impact of Exercise and Hyperlipidic Meal on Free Circulating DNA in Patients With Metastatic Colonic Cancer and Healthy Subjects N/A
Recruiting NCT05026268 - The Laparoscopic Right Colectomy With Intracoroporeal Anastomosis N/A
Not yet recruiting NCT03277235 - Effect of a Resilience Model-Based Care Plan in Newly Diagnosed Colorectal Cancer Patients N/A
Active, not recruiting NCT02730702 - Colon Cancer Risk-stratification Via Optical Analysis of Rectal Ultrastructure
Active, not recruiting NCT02959541 - PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer N/A
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Recruiting NCT02577627 - Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC N/A
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Recruiting NCT02526836 - Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer Phase 2/Phase 3